PMV Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 4, 2026, details the results of PMV Pharmaceuticals, Inc.'s virtual 2026 Annual Meeting of Stockholders. The meeting was held exclusively online via live webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- David H. Mack, Ph.D.: Elected with 15,693,907 votes FOR, 6,248,461 WITHHELD, and 6,975,412 BROKER NON-VOTES.
- Laurie Stelzer: Elected with 11,261,111 votes FOR, 10,681,257 WITHHELD, and 6,975,412 BROKER NON-VOTES.
- Both directors serve as Class III Directors until the 2029 annual meeting.
- Proposal 2: Non-Binding Advisory Vote on Executive Compensation
- Approved with 15,015,578 votes FOR, 6,468,718 AGAINST, and 458,072 ABSTAIN.
- Broker non-votes totaled 6,975,412.
- The Company will continue annual advisory votes until the next frequency vote expected in 2028.
- Proposal 3: Ratification of Independent Auditor
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2026.
- Voting results: 28,379,108 FOR, 536,302 AGAINST, and 2,370 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the definitive Proxy Statement (Schedule 14A) filed on April 22, 2026, for detailed executive compensation data.
- Confirm the tenure and specific responsibilities of the newly elected Class III Directors.
- Note the high number of broker non-votes (6,975,412) across all proposals, indicating significant shares held in street name where brokers lacked discretionary voting power.